In addition to OEM distribution, the collaboration provides flexibility for potential future expansion, which could include Dyadic supplying market-ready products for distribution or licensing ...

Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life ...

Portfolio of CTGrade cytokines and growth factors contain no animal- or human-derived materials Expansion of CTGrade portfolio resulting from the acquisition by FUJIFILM Irvine Scientific earlier this ...

Fermentation has evolved into precision fermentation, utilizing biotechnology to engineer microorganisms that produce ...

Activin-A is increasingly recognized as a potential therapeutic agent for conditions such as brain injury and inflammatory diseases. Studies have shown that it can help reduce damage and inflammation, ...

Dyadic Applied BioSolutions (NASDAQ: DYAI) shares advanced Monday. The Jupiter, Fla.-based company, a global biotechnology concern producing precision-engineered, animal-free proteins and enzymes for ...

Pichia pastoris has emerged as a central microbial host for recombinant protein production, offering a unique balance of rapid growth, capacity for post‐translational modifications, and ease of ...

Recombinant DNA (rDNA) refers to artificial DNA molecules that are created by combining genetic material from different sources. This technology involves the insertion of DNA fragments from one ...

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of ...

A new review outlines design principles and applications of synthetic membraneless organelles built through liquid-liquid phase separation for use in biotechnology.

Our animal-origin free recombinant proteins and enzymes portfolio, developed with Dyadic, augments Fermbox’s strategy ...